Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities.
Virchows Arch
November 2024
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Article Synopsis
- TTF-1 immunohistochemistry is commonly used to identify primary pulmonary adenocarcinomas, but it can also appear in various other cancer types.
- In a study involving 17,772 tumor samples, TTF-1 was found in 82 different tumor categories, indicating a broad range of malignancies where it may be present, spanning from thyroid cancers to neuroendocrine tumors.
- Although TTF-1 shows high sensitivity for distinguishing pulmonary adenocarcinomas, its specificity is low; combining TTF-1 with Napsin-A significantly enhances diagnostic accuracy.
Landscape analysis of the Kenyan policy on the treatment and prevention of diarrheal disease among under-5 children.
BMJ Open
August 2024
Department of Occupational and Environmental Health, The University of Iowa College of Public Health, Iowa City, Iowa, USA.
Objective: Diarrhoea remains a leading cause of morbidity and death among under-5 children in Kenya, despite multipronged policy and programme initiatives to increase access to treatment. This study interrogates the comprehensiveness and adequacy of Kenya's policies, frameworks and action plans for diarrheal management and prevention. The study seeks to identify policy and practice gaps that need to be filled to strengthen diarrhoea treatment and prevention among under-5 children in Kenya.
View Article and Find Full Text PDFGastrointestinal outcomes among older women with endometrial cancer.
Gynecol Oncol
August 2023
Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Objective: Treatment for endometrial cancer may contribute to bowel dysfunction and other gastrointestinal outcomes. We investigated the risk of several gastrointestinal diagnoses among older women with endometrial cancer and matched women without a history of cancer.
Methods: Women aged 66 years and older diagnosed with endometrial cancer during 2004-2017 (N = 44,386) and matched women without a known cancer history (N = 221,219) were identified in the SEER-Medicare linked data.
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
N Engl J Med
December 2022
From the Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill (E.S.D.); Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati (M.E.R., M.H.C.); Northwestern University Feinberg School of Medicine, Chicago (I.H.); Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York (M.C.), and Regeneron Pharmaceuticals, Tarrytown (X.S., M.P.K., M.A.K., J.D.H., B.B., E.M., B.A., N.A., W.K.L., M.F.W., M.R., D.R.W., G.D.Y., B.S., J.M., A.G., A.S.) - both in New York; Amsterdam University Medical Center, Amsterdam (A.J.B.); Hospital General de Tomelloso, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Madrid, and Instituto de Investigación Sanitaria de Castilla-La Mancha, Toledo - both in Spain (A.J.L.); Children's Hospital of Philadelphia, Philadelphia (J.M.S.); University of California, San Diego, La Jolla, and Rady Children's Hospital, San Diego - both in California (S.A.); Sanofi, Bridgewater, NJ (K.P., E.L.); Sanofi, Chilly-Mazarin, France (L.P.M.); and Sanofi, Cambridge, MA (N.P.).
Background: Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis.
Methods: We conducted a three-part, phase 3 trial in which patients 12 years of age or older underwent randomization in a 1:1 ratio to receive subcutaneous dupilumab at a weekly dose of 300 mg or placebo (Part A) or in a 1:1:1 ratio to receive 300 mg of dupilumab either weekly or every 2 weeks or weekly placebo (Part B) up to week 24. Eligible patients who completed Part A or Part B continued the trial in Part C, in which those who completed Part A received dupilumab at a weekly dose of 300 mg up to week 52 (the Part A-C group); Part C that included the eligible patients from Part B is ongoing.
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States.
Adv Ther
August 2022
Analysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Introduction: Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients with EoG/EoN versus without EoG/EoN in the USA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!